TxCell: financial information for the 3rd quarter of 2018

Valbonne, France, November 7, 2018 – TxCell SA (FR0010127662 – TXCL), a developer of cellular immunotherapies based on regulatory T cells (Tregs) for inflammation, autoimmunity and transplantation, today reports its financial information for the 3rd quarter of 2018.
As a reminder, following the acquisition by Sangamo Therapeutics, Inc. of a majority stake of TxCell on October 1, 2018, TxCell now operates as a subsidiary of Sangamo. Cash position and revenue as of September 30, 2018
As of September 30, 2018, the cash and cash equivalents amounted to EUR 6.6 million [1], including:

• Drawing of 5 monthly tranches of the financing program of notes convertible into shares with share subscription warrants (OCABSA) for a nominal amount of EUR 6.6 million. As of September 30, 2018, 56 notes remained unconverted, for a nominal amount of EUR 5.6 million. On October 1st, 2018, TxCell terminated its OCABSA financing program in the context of the closing of the acquisition by Sangamo of a majority stake of TxCell: 28 notes were converted into shares sold to Sangamo as part of the majority stake and 28 were early redeemed for a total amount of EUR 3.1 million.
• A EUR 4.5 million loan granted to TxCell by Sangamo in September 2018 to cover for working capital expenses.
• Partial pre-financing of the 2018 Research Tax Credit for EUR 1.0 million.

As expected, TxCell did not generate any revenue during the third quarter 2018.

[1] Unaudited

About TxCell – www.txcell.com

TxCell is a biotechnology company that develops platforms for innovative, personalized T cell immunotherapies for the treatment of severe inflammatory and autoimmune diseases with high unmet medical need.

TxCell is developing engineered antigen-specific T regulatory cells, where the antigen specificity is brought by a Chimeric Antigen Receptor (CAR) (CAR-Treg cells).

Based in Sophia-Antipolis, France, TxCell is listed on Euronext Paris and currently has 46 employees. Following the acquisition by Sangamo Therapeutics, Inc. of a majority stake of TxCell on October 1, 2018, TxCell now operates as a subsidiary of Sangamo.
This press release is for information purposes only and does not, and shall not, in any circumstances, constitute a public offering by TxCell nor a solicitation of an offer to subscribe for securities in any jurisdiction, including France. The persons in possession of this announcement shall then get knowledge of any local restrictions and shall comply with these restrictions.

Image Box is sending you this release as an identified important stakeholder in the life science sector. If you do not wish to receive periodic information from Image Box about key market players, please unsubscribe.Neil Hunter
Life Science & Corporate Communications Director
Image Box Ltd.
T: +44 (0) 20 8943 4685
D: +44 (0) 20 3747 3302
M: +44 (0) 777 333 6517
E: neil.hunter@imageboxpr.co.uk
W: www.imageboxpr.co.uk
Twitter: @Imageboxlspr

This e-mail (and any attachments) is confidential and may be privileged. If you are not the intended recipient of this message, please notify the sender and do not read, copy, use or disclose this communication to others. Any opinions or views expressed which are of a personal nature are not necessarily those of the company. The company reserves the right to monitor all e-mail communications.